"Health News - Medicine, Diet and Fitness"

PITTSBURGH, October 02, 2007 /PRNewswire-FirstCall/ — Mylan Inc. today announced the appointment of John Montgomery to the position of President, Asia Pacific following the completion of Mylan’s acquisition of Merck’s Generics Group today.

Mr. Montgomery has worked for over 30 years in the pharmaceuticals industry and has extensive experience in both patented and generics pharmaceutical products in the UK, U.S. and Asia Pacific regions. At Merck Generics, he served as Regional Director, Asia Pacific, and CEO of Alphapharm, Merck Generic’s business in Australia and the country’s leading pharmaceutical company as measured by prescriptions. Prior to joining Merck, he spent 18 years with Warner Lambert in the UK, U.S. and Australia in roles including Business Director, Europe; Vice President, Cardiovascular; Vice President of Portfolio Management for North America; and Regional President Australia/New Zealand. He served five years as Chairman of the Generic Medicines Industry Association (GMiA) in Australia.

(more…)

PITTSBURGH, October 02, 2007 /PRNewswire-FirstCall/ — Mylan announced today that it has completed its acquisition of Merck KGaA’s generics business (”Merck Generics”) to become one of the largest quality generics and specialty pharmaceuticals companies in the world. Mylan and Merck KGaA initially announced the signing of a definitive agreement under which Mylan would acquire Merck Generics for EUR 4.9 billion ($6.7 billion) in an all-cash transaction on May 12, 2007.

Robert J. Coury, Mylan’s Vice Chairman and Chief Executive Officer said, “The new Mylan now has all of the critical attributes we need to ensure future success and deliver powerful growth. We have enhanced scale and stability, a truly global reach, vertical and horizontal integration, and breadth and depth in our management team. Most importantly, we have a common purpose and dedication to executing on our strategy and delivering superior shareholder returns.”

(more…)

PITTSBURGH, October 02, 2007 /PRNewswire-FirstCall/ — Mylan Inc. today announced the appointment of Didier Barret to the position of President, EMEA (Europe, Middle East and Africa) following the completion of Mylan’s acquisition of Merck’s Generics Group today.

At Merck Generics, M. Barret most recently served as Region Director, EMEA, reporting to the CEO. He was promoted to that position in 2004 following his role as Area Director for Southern Europe, where he was responsible for France, Belgium, Italy, Spain and Portugal. He established Merck Generics’ first operations in France in 1995, growing the business to exceed euro 341 million in sales by 2006. Prior to this, M. Barret held several positions within Merck’s branded division, including sales and marketing in the UK and France.

(more…)

FDA, health care industry, and the medical community collaboration would share data via a national health IT system

CLEVELAND, October 02, 2007 /PRNewswire-FirstCall/ — Sidney Taurel, chairman and chief executive officer, Eli Lilly and Company, in a speech today at the Cleveland Clinic, called on the Men’s health care industry, medical community and U.S. government to actively collaborate on a Men’s health information technology system that would provide more rapid and useful insights on the effectiveness of medicines while improving drug safety.

(more…)

DALLAS, Oct. 1 — Preoperative evaluation of patients with heart disease should focus on determining current medical status, not providing clearance for surgery, according to an update of guidelines from the American Heart Association and American College of Cardiology. Action Points
Explain to interested patients that updated guidelines from the AHA and ACC recommend presurgical evaluations only for patients with unstable angina, decompensated heart failure, significant arrhythmias, or severe heart valve disease.

Point out that the guidelines discourage use of tests and interventions except as clearly indicated.
(more…)

HUENENBERG, Switzerland–(BUSINESS WIRE)–Sep 28, 2007 - Alcon, Inc. (NYSE:ACL) announced today that the company has gained control of 76.9 percent of WaveLight’s approximately 6.6 million issued and outstanding shares. As required by the German Security Purchase and Take-over Act, an additional two-week acceptance period will begin on September 29, 2007 and will continue through October 12, 2007. The company has received approvals from the competition authorities in Germany and Austria and is awaiting cartel clearances in China, Cyprus and Spain prior to closing of the transaction.

Through September 25, 2007, 3.10 million WaveLight shares were tendered to Alcon, equivalent to 47.1 percent of the issued and outstanding WaveLight shares. Also, Alcon has legally acquired 1.96 million WaveLight shares, or 29.9 percent of the issued and outstanding shares, either on the stock market or through direct purchase.

(more…)

- Executive changes announced -

REDWOOD CITY, Calif., October 01, 2007 /PRNewswire-FirstCall/ — PDL BioPharma, Inc. (PDL) today announced that its board of directors has recently decided to actively seek offers for the sale of the company as a whole or of its key assets. The decision is the result of PDL’s ongoing evaluation of strategic alternatives. The company will continue the previously announced process for the potential sale of its commercial products as part of the overall process. A final decision regarding the specific deal structures or transactions the company may enter into will be driven by the goal of maximizing stockholder value.

(more…)

JERUSALEM–(BUSINESS WIRE)–Sep 28, 2007 - Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that further to its press release dated September 8, 2007, the United States Court of Appeals for the Federal Circuit has denied Novartis’ emergency motion for an injunction pending its appeal of a September 5, 2007 District Court preliminary injunction ruling in favor of Teva. Teva can resume sales of its generic Famciclovir Tablets, AB-rated to Novartis’ Famvir Tablets.

About Teva

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal (more…)

SAN FRANCISCO–(BUSINESS WIRE)–Oct 1, 2007 - Five Prime Therapeutics, Inc., the protein therapeutics discovery and development company, today announced that it has successfully achieved a target discovery milestone in its research collaboration with Boehringer Ingelheim.

The research collaboration announced in April 2006, is a two-year alliance to discover novel therapeutic protein and antibody targets to treat rheumatoid arthritis and other diseases. In this collaboration, FivePrime applied its proprietary discovery platform and screened the complete set of secreted proteins and receptors in several high-content, multiplexed, cell-based assays to identify protein therapeutic and antibody targets. Boehringer Ingelheim has exclusive worldwide rights to develop and commercialize products and targets discovered.

(more…)

BOSTON, Oct. 1 — Dialysis patients exposed to gadolinium-containing contrast material during MRI may be at risk for nephrogenic systemic fibrosis, researchers found. Action Points
Explain to interested patients that kidney-failure patients have an increased risk of developing a painful, potentially lethal skin disorder that may be associated with prior exposure to a contrast agent used in MRI.

Analysis of 186 dialysis patients found that those who had undergone imaging studies using a gadolinium-containing contrast agent had more than 10 times the risk of developing the fibrosing disorder compared with patients with no exposure to the contrast agent, Jonathan Kay, M.D., of Harvard, and colleagues, reported in the October issue of Arthritis & Rheumatism.

(more…)